A Study to Evaluate the Safety of Augment™ Bone Graft
This study has been completed.
Information provided by (Responsible Party):
William Stanish, Capital District Health Authority, Canada
First received: February 2, 2011
Last updated: August 20, 2012
Last verified: August 2012
Is Augment Bone Graft plus Allograft safe to use for the treatment of osteochondral defects of the knee?
Defect of Articular Cartilage
Device: Augment Bone Graft
||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Pilot Study to Augment™ Bone Graft Plus Evaluate the Safety of Allograft for Treatment of Osteochondral Defects (OCD) of the Knee
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2012 (Final data collection date for primary outcome measure)
Single Arm.. Augment Bone Graft for Osteochondral Defects
Device: Augment Bone Graft
Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
Other Name: Bone Graft
Subjects will be 18 to 40 years with an osteochondral defects of the knee.They will be candidates for allograft and Augment Bone Graft will be added to the procedure. The safety of Augment Bone Graft plus allograft for osteochondral defects of the knee will be evaluated by type, frequency, severity and relatedness of adverse events to the device for a minimum of 24 weeks.Magnetic Resonance Imaging will be performed at 1,12 and 42 weeks to evaluate device integrity and surgical treatment of osteochondral defects. Computed tomography will be done at week 1 and week 24 to determine the healing status of the osteochondral defect.
|Ages Eligible for Study:
||18 Years to 40 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Prior Magnetic Resonance Imaging (MRI) evaluation or MRI on Screening.
- Subjects with Grade III osteochondral defect (OCD) of femoral condyle.
- Subjects with OCD > 1 cm.squared.
- Independent and ambulatory pts.
- Subjects from 18 to 40 years of age.
- Subject with a stable knee joint and similar stability on the opposite knee.
- Subject has knee x-ray with < 15 degrees of valgus and < 5 degrees varus.
- No deformity from previous fractures of tibia or fibula.
- BMI < 35.
- Subject has an American Association of Anaesthetists physical status classification of 1 or 2.
- Subject must present with pain > 3.0 cm according to the Visual Analogue Score.
- Subject has exhausted non operative treatment.
- Allergy to yeast derived products.
- Index knee has had cartilage repair in the last six months.
- Subjects with osteoarthritis,inflammatory arthritis, rheumatoid arthritis and avascular necrosis of index knee.
- Subject has contralateral knee complications which would interfere with rehabilitation
- Subject has implanted metallic devices that would prevent Magnetic Resonance Imaging (MRI).
- Subject has claustrophobia that would prevent MRI.
- Subject has had a malignancy or is being treated for a malignancy.
- Subject is physically or mentally compromised that would interfere with compliance.
- Subject is a prisoner or transient.
- Subject has a recent history (12 months) of alcohol abuse.
- Subject is pregnant, able to become pregnant but not practising birth control.
- Subject has an infection in the operative area.
- Subject has scheduled surgery on the contralateral knee over the course of the study.
- Subject requires another procedure in the index knee.
- Subject has had steroid therapy in the past six months.
- Subject is taking prescription pain medication for another indication other than the index knee.
- Subject is using nicotine in any form.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01290991
|Queen Elizabeth ll Health Sciences Centre
|Halifax, Nova Scotia, Canada, B3H 3A7 |
Nova Scotia Health Authority
||William D Stanish, MD
||Capital Dictrict Health Authority
No publications provided
||William Stanish, Medical Doctor, Capital District Health Authority, Canada
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 2, 2011
||August 20, 2012
||Canada: Health Canada
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 30, 2015
Connective Tissue Diseases